Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature.

PD‐1 inhibitors celiac‐like enteropathy immune‐related adverse effects immunotherapy nivolumab

Journal

Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 12 03 2019
revised: 13 06 2019
accepted: 22 06 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 20 9 2019
Statut: epublish

Résumé

Nivolumab may induce severe celiac-like enteropathy, that may appear very rapidly, after only two injections of nivolumab, and may be successfully treated with corticosteroids. This observation underlines the importance of histological analysis of duodenal biopsies and the necessity to rule out a real celiac disease in patients with nivolumab-induced diarrhea.

Identifiants

pubmed: 31534728
doi: 10.1002/ccr3.2342
pii: CCR32342
pmc: PMC6745396
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1689-1693

Déclaration de conflit d'intérêts

None declared.

Références

Mayo Clin Proc. 2013 Apr;88(4):414-7
pubmed: 23541015
PLoS One. 2016 Jul 29;11(7):e0160221
pubmed: 27472273
BMJ. 2018 Mar 14;360:k793
pubmed: 29540345
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):265-72
pubmed: 26122213
Curr Oncol Rep. 2018 Jul 31;20(9):72
pubmed: 30066230
Intern Med. 2018 Apr 15;57(8):1173-1176
pubmed: 29269640
Front Pharmacol. 2017 Oct 18;8:730
pubmed: 29093678
Clin Case Rep. 2019 Jul 28;7(9):1689-1693
pubmed: 31534728
Intern Med. 2018 May 1;57(9):1269-1272
pubmed: 29279482
Future Oncol. 2018 Dec;14(30):3187-3198
pubmed: 30188189
Aliment Pharmacol Ther. 2014 Nov;40(9):1103-9
pubmed: 25199794
BMC Gastroenterol. 2018 Aug 31;18(1):135
pubmed: 30170560
Medicine (Baltimore). 2017 Dec;96(48):e8931
pubmed: 29310385
Int Immunol. 2009 Sep;21(9):1037-45
pubmed: 19625381
J Clin Oncol. 2015 Jun 20;33(18):2092-9
pubmed: 25918278
J Crohns Colitis. 2016 Apr;10(4):395-401
pubmed: 26783344
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Scand J Gastroenterol. 2016;51(2):152-6
pubmed: 26291698
Hum Immunol. 2013 Sep;74(9):1214-8
pubmed: 23770251
J Cancer. 2018 Apr 12;9(9):1614-1622
pubmed: 29760800
Am J Case Rep. 2018 Mar 27;19:360-364
pubmed: 29581417
Clin Cancer Res. 2016 Nov 15;22(22):5461-5471
pubmed: 27169994
Clin Lung Cancer. 2018 Sep;19(5):e591-e596
pubmed: 29801705
Oncoimmunology. 2017 Jul 5;6(10):e1344805
pubmed: 29123955

Auteurs

Lucie Duval (L)

IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.

Sarah Habes (S)

IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.
University of Nantes Nantes France.

Thierry Chatellier (T)

Clinic of Estuaire Saint Nazaire France.

Pascale Guerzider (P)

Department of Pathology Hospital of Saint Nazaire Saint Nazaire France.

Céline Bossard (C)

Department of Pathology University Hospital of Nantes Nantes France.

Claude Masliah (C)

Clinic of Estuaire Saint Nazaire France.

Isabelle Archambeaud (I)

IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.

Yann Touchefeu (Y)

IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.
INSERMU1235, TENS University Bretagne Loire Nantes France.

Tamara Matysiak-Budnik (T)

IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.
University of Nantes Nantes France.
INSERMU1235, TENS University Bretagne Loire Nantes France.

Classifications MeSH